"Hengrui Medicine: HRS-5041 tablets receive drug clinical trial approval notification."

Hengrui Pharmaceuticals announced that the company and its subsidiary, Chengdu Shengdi Pharmaceuticals Co., Ltd., recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-5041 tablets. Clinical trials will be conducted in the near future. HRS-5041 is a new, efficient, and selective AR-PROTAC small molecule developed by the company, intended for the treatment of prostate cancer. As of now, the cumulative research and development investment in the HRS-5041 project is approximately 69.19 million yuan.